Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow

Molecular Genetics and Metabolism

Volumn 79, Issue 4, 2003, Pages 233-244

  Zheng, Yi ^a   Rozengurt, Nora ^a   Ryazantsev, Sergey ^a   Kohn, Donald B ^b   Satake, Noriko ^b   Neufeld, Elizabeth F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Bone marrow transplantation; Gene therapy; Glycosaminoglycan; Hurler; Lysosome; Mouse model; Mucopolysaccharidosis; Retroviral vector; L Iduronidase

Indexed keywords

COMPLEMENTARY DNA; LEVO IDURONIDASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER EPITHELIUM; BONE MARROW; BONE MARROW TRANSPLANTATION; BRAIN; BRAIN CORTEX; CARTILAGE; CHEMICAL PARAMETERS; CHOROID PLEXUS; COMPARATIVE STUDY; CONTROLLED STUDY; DONOR; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EXPERIMENTAL TEST; FEMALE; GENE THERAPY; HEMATOPOIETIC CELL; HURLER SYNDROME; KIDNEY; KNOCKOUT MOUSE; LIVER; MALE; MICROGLIA; MICROSCOPY; MOUSE; NERVE CELL; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; SPLEEN; STORAGE DISEASE; THALAMUS; WILD TYPE; Y CHROMOSOME;

EID: 0041387505     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(03)00116-1     Document Type: Article

References (43)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. eighth ed. 2001;3421-3452 McGraw-Hill, New York.
2. Krawczak M., Cooper D.N. The human gene mutation database. Trends Genet. 13:1997;121-122.
3. Scott H.S., Bunge S., Gal A., Clarke L.A., Morris C.P., Hopwood J.J. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum. Mutat. 6:1995;288-302.
4. Fratantoni J.C., Hall C.W., Neufeld E.F. The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation. Proc. Natl. Acad. Sci. USA. 64:1969;360-366.
5. Bach G., Friedman R., Weissmann B., Neufeld E.F. The defect in the Hurler and Scheie syndromes: deficiency of α-L-iduronidase. Proc. Natl. Acad. Sci. USA. 69:1972;2048-2051.
6. Sando G.N., Neufeld E.F. Recognition and receptor-mediated uptake of a lysosomal enzyme, alpha-L-iduronidase, by cultured human fibroblasts. Cell. 12:1977;619-627.
7. Shull R.M., Kakkis E.D., McEntee M.F., Kania S.A., Jonas A.J., Neufeld E.F. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. USA. 91:1994;12937-12941.
8. Kakkis E.D., McEntee M.F., Schmidtchen A., Neufeld E.F., Ward D.A., Gompf R.E., Kania S., Bedolla C., Chien S.L., Shull R.M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 58:1996;156-167.
9. Kakkis E.D., Schuchman E., He X., Wan Q., Kania S., Wiemelt S., Hasson C.W., O'Malley T., Weil M.A., Aguirre G.A., Brown D.E., Haskins M.E. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol. Genet. Metab. 72:2001;199-208.
10. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344:2001;182-188.
11. Hobbs J.R., Hugh-Jones K., Barrett A.J., Byrom N., Chambers D., Henry K., James D.C., Lucas C.F., Rogers T.R., Benson P.F., Tansley L.R., Patrick A.D., Mossman J., Young E.P. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 2:1981;709-712.
12. Hopwood J.J., Vellodi A., Scott H.S., Morris C.P., Litjens T., Clements P.R., Brooks D.A., Cooper A., Wraith J.E. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J. Inherit. Metab. Dis. 16:1993;1024-1033.
13. Peters C., Balthazor M., Shapiro E.G., King R.J., Kollman C., Hegland J.D., Henslee-Downey J., Trigg M.E., Cowan M.J., Sanders J., Bunin N., Weinstein H., Lenarsky C., Falk P., Harris R.et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 87:1996;4894-4902.
14. Vellodi A., Young E.P., Cooper A., Wraith J.E., Winchester B., Meaney C., Ramaswami U., Will A. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch. Dis. Child. 76:1997;92-99.
15. Peters C., Shapiro E.G., Anderson J., Henslee-Downey P.J., Klemperer M.R., Cowan M.J., Saunders E.F., deAlarcon P.A., Twist C., Nachman J.B., Hale G.A., Harris R.E., Rozans M.K., Kurtzberg J., Grayson G.H.et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood. 91:1998;2601-2608.
16. Krivit W., Sung J.H., Shapiro E.G., Lockman L.A. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 4:1995;385-392.
17. Hahn C.N., del Pilar Martin M., Zhou X.Y., Mann L.W., d'Azzo A. Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc. Natl. Acad. Sci. USA. 95:1998;14880-14885.
18. Huang M.M., Wong A., Yu X., Kakkis E., Kohn D.B. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts. Gene Ther. 4:1997;1150-1159.
19. Fairbairn L.J., Lashford L.S., Spooncer E., McDermott R.H., Lebens G., Arrand J.E., Arrand J.R., Bellantuono I., Holt R., Hatton C.E., Cooper A., Besley G.T., Wraith J.E., Anson D.S., Hopwood J.J.et al. Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow. Proc. Natl. Acad. Sci. USA. 93:1996;2025-2030.
20. Shull R., Lu X., Dube I., Lutzko C., Kruth S., Abrams-Ogg A., Kiem H.P., Goehle S., Schuening F., Millan C., Carter R. Humoral immune response limits gene therapy in canine MPS I [letter]. Blood. 88:1996;377-379.
21. Lutzko C., Kruth S., Abrams-Ogg A.C., Lau K., Li L., Clark B.R., Ruedy C., Nanji S., Foster R., Kohn D., Shull R., Dube I.D. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood. 93:1999;1895-1905.
22. Meertens L., Zhao Y., Rosic-Kablar S., Li L., Chan K., Dobson H., Gartley C., Lutzko C., Hopwood J., Kohn D., Kruth S., Hough M.R., Dube I.D. In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. Hum. Gene Ther. 13:2002;1809-1820.
23. Vogler C., Barker J., Sands M.S., Levy B., Galvin N., Sly W.S. Murine mucopolysaccharidosis VII: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease. Pediatr. Dev. Pathol. 4:2001;421-433.
24. Zheng Y., Zhou J., Rozengurt N., Ryazantsev A., Li H.H., Kohn D.B., Neufeld E.F. Treatment of the murine model of MPSI by transplantation of bone marrow and of genetically modified bone marrow. Am. J. Hum. Genet. 69(Suppl.):2001;679.
25. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. USA. 100:2003;1902-1907.
26. Clarke L.A., Russell C.S., Pownall S., Warrington C.L., Borowski A., Dimmick J.E., Toone J., Jirik F.R. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum. Mol. Genet. 6:1997;503-511.
27. Russell C., Hendson G., Jevon G., Matlock T., Yu J., Aklujkar M., Ng K.Y., Clarke L.A. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin. Genet. 53:1998;349-361.
28. Challita P.M., Skelton D., el-Khoueiry A., Yu X.J., Weinberg K., Kohn D.B. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69:1995;748-755.
29. Miller A.D., Rosman G.J. Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:1989;980-982. 984-986, 989-990.
30. Soneoka Y., Cannon P.M., Ramsdale E.E., Griffiths J.C., Romano G., Kingsman S.M., Kingsman A.J. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23:1995;628-633.
31. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA. 90:1993;8033-8037.
32. Case S.S., Price M.A., Jordan C.T., Yu X.J., Wang L., Bauer G., Haas D.L., Xu D., Stripecke R., Naldini L., Kohn D.B., Crooks G.M. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. USA. 96:1999;2988-2993.
33. Markowitz D., Goff S., Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1988;1120-1124.
34. Robbins P.B., Skelton D.C., Yu X.J., Halene S., Leonard E.H., Kohn D.B. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Natl. Acad. Sci. USA. 95:1998;10182-10187.
35. Rome L.H., Weissmann B., Neufeld E.F. Direct demonstration of binding of a lysosomal enzyme, alpha-L-iduronidase, to receptors on cultured fibroblasts. Proc. Natl. Acad. Sci. USA. 76:1979;2331-2334.
36. Kakkis E.D., Matynia A., Jonas A.J., Neufeld E.F. Overexpression of the human lysosomal enzyme α-L-iduronidase in Chinese hamster ovary cells. Protein Expr. Purif. 5:1994;225-232.
37. Li H.H., Yu W.H., Rozengurt N., Zhao H.Z., Lyons K.M., Anagnostaras S., Fanselow M.S., Suzuki K., Vanier M.T., Neufeld E.F. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc. Natl. Acad. Sci. USA. 96:1999;14505-14510.
38. Breider M.A., Shull R.M., Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am. J. Pathol. 134:1989;677-692.
39. Whitley C.B., Belani K.G., Chang P.N., Summers C.G., Blazar B.R., Tsai M.Y., Latchaw R.E., Ramsay N.K., Kersey J.H. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am. J. Med. Genet. 46:1993;209-218.
40. Skelton D., Satake N., Kohn D.B. The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther. 8:2001;1813-1814.
41. Skorupa A.F., Fisher K.J., Wilson J.M., Parente M.K., Wolfe J.H. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp. Neurol. 160:1999;17-27.
42. Bosch A., Perret E., Desmaris N., Trono D., Heard J.M. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11:2000;1139-1150.
43. Brooks A.I., Stein C.S., Hughes S.M., Heth J., McCray P.M. Jr., Sauter S.L., Johnston J.C., Cory-Slechta D.A., Federoff H.J., Davidson B.L. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA. 99:2002;6216-6221.